NON-SMALL CELL LUNG CARCINOMA
Clinical trials for NON-SMALL CELL LUNG CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CARCINOMA trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test drug duo to reboot immune system against tough cancers
Disease control Recruiting nowThis early-stage trial is testing whether adding a pill called ruxolitinib to an immunotherapy drug (retifanlimab) is safe and can help control advanced lung or kidney cancer that has started growing again after prior immunotherapy. The study will enroll about 40 participants to …
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
First-of-its-Kind pill targets Cancer's 'Guardian Gene' mutation
Disease control Recruiting nowThis study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for lung cancer patients: experimental drug combo enters major trial
Disease control Recruiting nowThis study is testing whether combining two investigational drugs works better than standard treatment for advanced non-small cell lung cancer. Researchers will enroll 252 adults who haven't received prior treatment for their advanced cancer to test safety, find the best dose, an…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First patients receive experimental pill targeting Hard-to-Treat cancers
Disease control Recruiting nowThis is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see …
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for Tough-to-Treat lung cancer: major trial tests promising drug
Disease control Recruiting nowThis study is testing if a new drug called PF-08046054 works better than the standard chemotherapy drug docetaxel for people with advanced non-small cell lung cancer. It is for adults whose cancer has spread, cannot be removed by surgery, and has gotten worse despite trying other…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New Two-Target drug enters human testing for Tough-to-Treat lung cancer
Disease control Recruiting nowThis study is testing a new experimental drug called AZD2936 for people with advanced or metastatic non-small cell lung cancer. The main goals are to find a safe dose and see if the drug helps shrink tumors, especially in patients whose cancer has worsened after previous immunoth…
Matched conditions: NON-SMALL CELL LUNG CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC